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BACKGROUND: This study quantified the risk of urinary bladder neoplasms in cancer patients taking into account the age at first
diagnosis, the gender of the patients and the lead time between diagnoses.
METHODS: We used standardised incidence ratios (SIRs) to compare the incidence of bladder tumours in 967767 cancer patients with
the incidence rate in the general Swedish population. A total of 3324 male and 1560 female patients developed bladder tumours at
least 1 year after first cancer diagnosis.
RESULTS: After bladder and renal pelvis cancers, the SIRs of bladder neoplasms were higher in female than in male patients. Men
affected by lung, stomach and larynx tumours belonged to the population at high risk for bladder cancer. Treatment of breast, ovarian
and cervical cancers seems to contribute to the subsequent development of bladder neoplasms. Long latencies (16–25 years) were
observed after testicular, cervical and endometrial cancers. Detection bias had an important role after prostate cancer.
Chemotherapy with cyclophosphamide and cisplatin, and also radiotherapy, seem to increase the risk of subsequent neoplasms in the
bladder.
CONCLUSIONS: These population-based results may help urologists to assess the risk of bladder neoplasms in cancer survivors. Our
data should guide ongoing studies that investigate the effectiveness of bladder cancer screening in cancer patients.
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The investigation of the development of urinary bladder neo-
plasms in cancer patients may provide unique clues to advance
the understanding of the aetiology of bladder cancer. Tobacco
smoking, occupational exposure to aromatic and heterocyclic
amines, and probably chronic bladder infections are estab-
lished risk factors for bladder cancer (Nordlund et al, 1997;
Brennan et al, 2000, 2001; IARC, 2004; Gandini et al, 2008;
Kiemeney et al, 2008). Variants in genes coding for xenobiotic-
transforming enzymes and polymorphisms in DNA repair genes
may also modify cancer susceptibility (Easton et al, 2007; Kellen
et al, 2007; Murta-Nascimento et al, 2007b; Sanderson et al, 2007;
Andrew et al, 2008). In addition to detection bias and risk factors
shared by cancer of distinct types, for example, tobacco smoking is
a risk factor for both lung and bladder cancers, second primary
neoplasms may be related to the treatment of the first tumour.
Radiotherapy to the pelvic area and chemotherapy with cyclopho-
sphamide increase the risk of bladder cancer (Murta-Nascimento
et al, 2007a).
After laryngeal cancer, bladder cancer shows the highest excess
of risk for men compared with that for women in Sweden and the
excess risk increases with age (National Board of Health and
Welfare, 2007; Bermejo et al, 2008). In Sweden in 2005, the
incidence ratio of bladder cancer in men compared with that in
women was 3.1 in the age band 50 to 54 years and this ratio
increased to 4.1 for the age band 80–84 years (Engholm et al,
2007). Recent meta-analyses imply that, at least in the western
world, smoking can only partially explain this gender difference in
the incidence of bladder cancer (Hemelt et al, 2008).
The objective of this article was to examine the risk of bladder
neoplasms after cancer diagnosis, taking into account the gender
of the patients, the age of diagnosis of the first cancer and the time
since first diagnosis. These data may be relevant for clinical
counselling, future development of screening programmes, and to
advance the understanding of the aetiology of the disease. The
present results were based on around 3000 male and 1500 female
cancer patients who developed bladder tumours at least 1 year
after first cancer diagnosis. In addition to the large sample size
from a single country, the nationwide complete coverage and the
reliability of cancer data represented important advantages of this
study.
MATERIAL AND METHODS
The Swedish Family-Cancer Database includes persons born in
Sweden after 1931, totalling more than 11.8 million persons and
more than 1.2 million tumour notifications – for a detailed
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sdescription of the Database and its last update see reference
Bermejo et al (2008). Cancer cases were retrieved from the Swedish
Cancer Registry, which relies on separate compulsory notifications
of cases from clinicians who diagnosed a neoplasm and from
pathologists/cytologists. Second cancers were classified as such
by the Cancer Registry, including synchronous tumours. The
percentage of histologically or cytologically verified cases of cancer
has been close to 100% (National Board of Health and Welfare,
2007). Unfortunately, the Swedish Cancer Registry lacks historic
clinical and treatment data. In this study, 967767 cancer patients
were followed up from first cancer diagnosis until death,
recurrence, detection of a second primary cancer, emigration or
31 December 2006, whichever came first.
The incidences of second primary urinary bladder malignancies
among cancer patients were compared with the rates of first
primary bladder cancers in the general Swedish population
by standardised incidence ratios (SIRs) and 95% confidence
intervals (CIs), adjusting for covariates age (5-year bands), sex,
socioeconomic index (six groups), region (four groups) and
calendar year (1961 to 1964, 1965 to 1969, and so on to 2000
to 2006). Separate analyses were carried out according to age
at first cancer diagnosis (before age 20 years, 20 to 39, 40 to 59
and after 60 years). The SIR applies indirect standardisation,
which is particularly suitable for cells with small numbers of
subjects. In this method the observed number of cases is divided
by the expected number of cases, calculated from the whole
background population of 11.8 million individuals. The investi-
gation of 36 types of cancer may result in false positive
associations due to multiple comparisons. To alleviate this
problem, associations were reported according to 0.05 and 0.01
significance levels. Kidney cancers were separated into cancers of
the renal pelvis (International Classification of Diseases, 7th
revision (ICD7)¼1801) and the renal parenchyma (ICD7¼1800).
Cancer types were classified as ‘recurrent sites’ (urinary bladder
and renal pelvis), ‘smoking-related sites’ and ‘non-smoking-related
sites’.
RESULTS
Table 1 shows gender-specific SIRs of bladder tumours in cancer
patients. Results are presented for ‘any time’ and ‘at least 1 year’
between the two diagnoses. For example, 14 women developed
bladder cancer after upper aerodigestive tract cancer. Their risk of
bladder cancer was 2.22 times higher than the averaged risk in the
general female population. When follow-up was started 1 year after
first diagnosis, the number of patients decreased to 13, the SIR was
2.54. To limit the possible effect of surveillance bias due to first
diagnosis, following description focuses on tumours diagnosed at
least one year apart. Significant findings at the 0.01 confidence
level are underlined in Table 1.
Among female patients, the highest increases in risk were
observed after renal pelvis (SIR¼61.4) and bladder (SIR¼10.5)
neoplasms. The SIRs higher than 3.0 were found in women affected
by cancer in the cervix, other female genital organs, stomach and
endometrium. Statistically significant (Po0.01) increases were also
observed after ovarian, lung, rectal, colonic and breast cancers.
The SIR after cancer at any smoking-related site was 3.84 and
it equalled SIR¼1.77 after any non-smoking-related site. The
averaged SIR of bladder neoplasms in women 1 year after
diagnosis of any type of cancer was 2.22. Among men, the highest
increases in the risk of bladder cancer were also observed after
renal pelvis (SIR¼23.4) and bladder (SIR¼5.27) neoplasms.
Interestingly, SIRs of recurrent neoplasms were significantly lower
for male than for female patients. The highest SIRs in men were
found after liver, eye and lung cancers. The SIRs in Table 1 permit
to compare the risks of bladder neoplasms after diagnosis of
different types of cancer. For example, men affected by lung cancer
were at a higher risk of bladder tumours than prostate cancer
patients (disjoint CIs).
In addition to shared risk factors, the diagnosis of two cancers in
the same individual may be related to the treatment of the first
tumour. Results in Table 2, based on tumours diagnosed at least
1 year apart, may help to discriminate between these two
components. For example, Table 1 shows the SIR of 2.57 after
stomach cancer in men. Bladder cancer patients did not show an
increased risk of stomach cancer, thus favouring the effect of
stomach cancer treatment over shared risk factors. The association
between colorectal and bladder cancers was noticed in both
directions, with similar risk increase in women. In men, the SIRs
after bladder cancer were statistically lower than the SIRs in
the opposite sequence. The association between lung and bladder
tumours was observed in both directions. Female patients
diagnosed with bladder cancer did not show an increased risk of
breast and ovarian tumours, and a preventive effect was found for
cervical cancer (SIR¼0.41). These data probably signalise a
contribution of treatment of breast, ovarian and cervical cancers
to the development of subsequent bladder neoplasms. The SIR of
endometrial cancer after bladder tumours was 4.83, higher than the
SIR of bladder cancer after endometrial cancer. The relative risk of
prostate neoplasms in bladder cancer patients (SIR¼1.41) was
significantly lower than the risk increase in the opposite direction.
Figure 1 shows absolute incidence rates for cancer types with at
least 100 patients affected by second bladder neoplasms, and for
age intervals with at least five observed cases. The incidence rates
of bladder cancer in the general population are also shown. Among
men, the highest recurrence rate was observed among renal pelvis
cancer patients (around 2 cases per 1000 person-years in the age
band 75 to 85 years). The incidence was higher than 200 per 10
5
person-years in men with bladder cancer older than 55 years. Men
affected by colon cancer reached an incidence of 300 per 10
5 person-
years at age 80–85 years. More modest incidences were found
among female patients. Recurrence rates after urinary bladder
cancer were the highest (around 270 cases per 10
5 person-years) at
age 70–79 years. Cervical cancer survivors showed the highest rate
of bladder neoplasms at age 80–85 years. The estimated incidence
of second bladder neoplasms in endometrial cancer patients was
around 180 per 10
5 person-years in the age period of 80–85 years.
Consideration of the age of diagnosis of the first malignancy,
together with patient’s age, may result in more accurate estimates
of the risk to develop secondary bladder neoplasms. Table 3 shows
SIRs according to these categories. Results are only presented for
cancer types with at least 100 patients affected by second bladder
tumours, for testicular cancer and for cells with observed cases.
Only tumours diagnosed at least 1 year apart were included in the
calculations.
The SIRs of recurrent bladder neoplasms in bladder cancer
patients decreased with age in both men and women, and they
were markedly higher in women compared with those in men. The
SIRs after renal pelvis cancer also decreased with increasing ages
and with increasing lead times. The SIRs in lung cancer patients
showed a U-shaped pattern. Cervical cancer patients showed the
highest SIRs of bladder neoplasms in the age period of 56–65 years
(SIR¼5.83) and women diagnosed with cervical cancer at age
40–59 years showed the highest increase in risk of bladder
neoplasms 16–25 years after the first diagnosis. The SIR after renal
parenchyma cancer was almost constant.
Colorectal cancer patients showed decreasing SIRs with
increasing ages. The SIRs according to the age of diagnosis of
the first malignancy are presented in the three right columns
of Table 3. For example, the SIR of bladder cancer was 1.63 in
patients aged 66–75 years who were diagnosed with colorectal
cancer at the age of 40–59 years. Women affected by breast cancer
showed decreasing SIRs with increasing ages. The risk pattern was
bimodal in women diagnosed at age 40–59 years, with the first
maximum shortly after first diagnosis and a second maximum after
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s16–25 years. Long latency times were also noticed in women
affected by endometrial cancer. Prostate cancer patients showed
decreasing SIRs with increasing ages, and with increasing time
since first diagnosis. By contrast, the pattern of risk in men affected
by testicular cancer favoured treatment effects. Men affected by
non-Hodgkin lymphoma showed SIR maxima in the age intervals
‘before age 45 years’, ‘56–65 years’ and ‘after 85 years of age’.
DISCUSSION
In the near future, urologists will face an increasing number of
cancer survivors visiting their practices. This study investigates the
risk of second bladder neoplasms in cancer patients. We used two
different strategies to discriminate between risk factors shared by
subsequent malignancies and the effect of first cancer treatment.
First, we compared the SIRs of bladder tumours in cancer patients
with the SIRs of second cancers in patients affected by bladder
tumours. The second approach investigated the pattern of risk
after first tumours: asynchronous constant or decreasing relative
risks may favour shared risk factors, whereas increasing risks with
increasing lead time should point to treatment effects (Heard et al,
2005). There is an excellent literature on the development of
bladder tumours after specific types of cancer, for example after
prostate, oesophageal, testicular, cervical and lung tumours, and
after lymphomas (Kaldor et al, 1987; Pettersson et al, 1990; Pathak
Table 1 Number and SIRs of second bladder tumours in cancer patients
Women Men
Time between two diagnoses Time between two diagnoses
Any time At least 1 year Any time At least 1 year
First cancer type N SIR (95% CI) N SIR (95% CI) N SIR (95% CI) N SIR (95% CI)
Recurrent neoplasms
Urinary bladder 189 19.6 (17.0–22.7) 132 10.5 (8.87–12.5) 655 6.47 (5.98–6.99) 501 5.66 (5.19–6.19)
Renal pelvis 93 205 (167–251) 48 61.4 (46.3–81.6) 187 61.8 (53.5–71.3) 108 23.4 (19.4–28.3)
Smoking-related cancer sites (excluding recurrent neoplasms)
Upper aerodigestive tract 14 2.22 (1.32–3.76) 13 2.54 (1.47–4.37) 105 1.18 (0.98–1.43) 93 1.18 (0.96–1.45)
Oesophagus 10 2.17 (1.17–4.03) 6 2.64 (1.19–5.87)
Stomach 19 2.87 (1.83–4.51) 16 3.29 (2.01–5.37) 103 2.56 (2.11–3.11) 80 2.57 (2.06–3.20)
Anus 7 3.16 (1.51–6.63) 5 2.12 (0.88–5.09) 7 2.75 (1.31–5.77) 5 2.63 (1.10–6.33)
Pancreas 1 0.69 (0.10–4.93) 9 1.47 (0.77–2.83) 4 0.67 (0.25–1.80)
Nose 2 1.23 (0.31–4.91) 1 0.51 (0.07–3.60) 13 1.60 (0.93–2.75) 11 1.48 (0.82–2.66)
Larynx 96 2.32 (1.90–2.84) 88 2.34 (1.90–2.89)
Lung 24 2.69 (1.80–4.02) 18 2.21 (1.39–3.51) 151 2.95 (2.51–3.46) 101 2.91 (2.40–3.54)
Cervix 278 5.60 (4.97–6.31) 258 5.45 (4.82–6.17)
Renal parenchyma 38 2.82 (2.05–3.88) 25 1.57 (1.06–2.33) 119 2.33 (1.94–2.78) 84 1.38 (1.12–1.71)
Any smoking-related 383 4.01 (3.62–4.43) 336 3.84 (3.45–4.27) 613 2.08 (1.92–2.25) 472 1.75 (1.60–1.91)
Non-smoking-related cancer sites
Salivary glands 5 1.85 (0.77–4.45) 5 1.97 (0.82–4.75) 18 1.59 (1.00–2.53) 15 1.48 (0.89–2.46)
Small intestine 4 1.06 (0.40–2.83) 4 1.22 (0.46–3.26) 16 1.43 (0.88–2.34) 11 0.96 (0.53–1.72)
Colon 102 1.87 (1.54–2.27) 89 1.71 (1.39–2.10) 294 1.71 (1.52–1.92) 253 1.86 (1.65–2.11)
Rectum 43 1.77 (1.31–2.38) 38 1.77 (1.28–2.43) 174 2.50 (2.15–2.90) 135 2.63 (2.22–3.11)
Liver 6 2.66 (1.19–5.91) 1 0.29 (0.04–2.04) 20 14.1 (9.11–21.9) 11 3.56 (1.97–6.43)
Breast 378 1.77 (1.60–1.96) 352 1.42 (1.28–1.58) 4 0.44 (0.17–1.18) 3 0.37 (0.12–1.14)
Endometrium 212 2.80 (2.45–3.21) 206 3.13 (2.73–3.60)
Ovary 85 2.63 (2.13–3.26) 82 2.85 (2.29–3.54)
Other female genital 25 4.45 (3.01–6.59) 19 3.99 (2.54–6.25)
Prostate 1721 3.99 (3.81–4.19) 1000 2.05 (1.93–2.19)
Testis 70 2.91 (2.30–3.68) 65 2.65 (2.08–3.38)
Other male genital 24 1.90 (1.28–2.84) 17 1.39 (0.86–2.24)
Melanoma 39 1.24 (0.90–1.70) 37 1.26 (0.92–1.75) 139 1.29 (1.10–1.53) 127 1.36 (1.14–1.62)
Skin, squamous cell 52 1.66 (1.26–2.18) 46 1.35 (1.01–1.80) 258 1.17 (1.03–1.32) 226 1.27 (1.12–1.45)
Eye 2 0.63 (0.16–2.53) 2 0.66 (0.16–2.64) 16 6.00 (3.68–9.80) 13 3.09 (1.80–5.33)
Nervous system 33 1.44 (1.02–2.02) 31 1.42 (1.00–2.01) 59 1.13 (0.87–1.45) 52 1.08 (0.82–1.41)
Thyroid gland 15 0.93 (0.56–1.55) 15 0.97 (0.59–1.61) 15 2.00 (1.20–3.31) 14 1.96 (1.16–3.31)
Endocrine glands 44 1.12 (0.84–1.51) 40 1.08 (0.79–1.47) 53 1.21 (0.93–1.59) 49 1.28 (0.96–1.69)
Bone 1 0.57 (0.08–4.07) 1 0.60 (0.09–4.29) 7 1.56 (0.74–3.27) 6 1.45 (0.65–3.23)
Connective tissue 8 1.15 (0.58–2.30) 8 1.24 (0.62–2.49) 25 1.57 (1.06–2.32) 21 1.53 (1.00–2.34)
Hodgkin disease 3 1.25 (0.40–3.87) 2 0.93 (0.23–3.70) 17 1.39 (0.86–2.23) 17 1.55 (0.96–2.49)
Non-Hodgkin lymphoma 29 1.51 (1.05–2.18) 27 1.61 (1.10–2.35) 122 1.98 (1.66–2.37) 102 1.95 (1.60–2.36)
Myeloma 8 1.08 (0.54–2.17) 4 0.69 (0.26–1.84) 18 0.60 (0.38–0.95) 14 0.47 (0.28–0.79)
Leukaemia 22 2.18 (1.44–3.32) 17 1.39 (0.87–2.24) 92 1.83 (1.50–2.25) 67 1.66 (1.31–2.11)
Any non-smoking related 1116 1.80 (1.70–1.91) 1026 1.77 (1.66–1.88) 3162 2.04 (1.97–2.12) 2218 1.52 (1.46–1.58)
Any site 1807 2.47 (2.35–2.60) 1560 2.22 (2.11–2.34) 4657 2.40 (2.33–2.48) 3324 1.86 (1.79–1.92)
Abbreviations: CI¼confidence interval; SIR¼standardised incidence ratio. Bold type represents a significant increase at the 5% confidence level, underlined SIRs were higher
than 1.00 at the 1% confidence level.
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set al, 1992; Bjorge et al, 1995; Bokemeyer and Schmoll, 1995; Travis
et al, 1995, 1997; Levi et al, 1996, 1999; Fisher et al, 1997; Teppo
et al, 2001; Dores et al, 2002; Brennan et al, 2005; Heard et al, 2005;
Liauw et al, 2006; Bostrom and Soloway, 2007; Chaturvedi et al,
2007; Kellen et al, 2007; Landgren et al, 2007; Muller et al, 2007;
Chuang et al, 2008; Singh et al, 2008). The main advantage of this
study was the simultaneous investigation of the most common
types of cancer before bladder tumours using a uniform reference
population. Unfortunately, information on disease grade, treat-
ment and smoking history was not available. The number of
affected patients was small for some combinations of first cancer
types and age categories, and chance due to multiple comparisons
probably explains some of the detected associations.
In addition to lung and bladder cancers, tobacco smoking has
been related to an increased risk of kidney, oral cavity, larynx,
oesophagus, pancreas and stomach tumours (IARC, 2004). Table 4
shows a summary of risk factors that may result in the
development of urinary bladder neoplasms in cancer patients.
Although this list is not comprehensive and some readers would
attribute a rather minor effect to some of the enumerated factors,
we consider that the table may facilitate the interpretation of
present results in the following discussion.
With the exception of pancreatic cancer, characterised by a very
poor prognosis, our data confirmed that patients affected by
tobacco-related malignancies were at an increased risk of bladder
tumours. Tobacco smoking confers the highest risk to lung cancer,
which was reflected in SIRs of 2.21 for women and 2.91 for men.
The estimated SIRs were in agreement with a previous Finnish
study that investigated the risk of new primary tumours in lung
cancer patients and suggested that the increased use of cytostatic
drugs may increase the risk of second tumours (Teppo et al, 2001).
Recent studies have shown that patients with non-muscle invasive
bladder cancer suffer a high incidence of mortality from lung
cancer and they might constitute a suitable population for a lung
Table 2 Number and SIRs of second tumours in urinary bladder cancer patients
Women Men
Second cancer type N SIR (95% CI) N SIR (95% CI)
Recurrent neoplasms
Urinary bladder 132 10.5 (8.87–12.5) 501 5.66 (5.19–6.19)
Renal pelvis 48 40.1 (30.0–53.5) 154 34.5 (29.2–40.7)
Smoking-related cancer sites (excluding recurrent neoplasms)
Upper aerodigestive tract 6 0.73 (0.33–1.63) 70 1.28 (1.01–1.61)
Oesophagus 7 4.53 (2.16–9.51) 47 0.87 (0.66–1.16)
Stomach 19 0.95 (0.60–1.49) 188 1.04 (0.90–1.20)
Anus 2 1.36 (0.34–5.44) 6 1.23 (0.55–2.76)
Pancreas 42 1.54 (1.14–2.09) 120 1.23 (1.02–1.47)
Nose 1 0.38 (0.05–2.73) 7 1.13 (0.54–2.38)
Larynx 1 0.83 (0.12–5.89) 48 1.35 (1.02–1.79)
Lung 115 3.32 (2.76–3.99) 645 2.00 (1.85–2.17)
Cervix 13 0.41 (0.24–0.71)
Renal parenchyma 16 0.60 (0.37–0.98) 91 1.38 (1.12–1.69)
Any smoking-related 222 1.58 (1.38–1.80) 1222 1.50 (1.42–1.59)
Non-smoking-related cancer sites
Salivary glands 3 2.16 (0.70–6.71) 7 1.35 (0.64–2.85)
Small intestine 5 0.82 (0.34–1.97) 32 1.81 (1.27–2.56)
Colon 95 1.76 (1.44–2.15) 352 1.21 (1.09–1.34)
Rectum 46 1.67 (1.25–2.24) 187 1.22 (1.06–1.41)
Liver 34 2.06 (1.47–2.88) 112 1.96 (1.63–2.36)
Breast 195 0.98 (0.85–1.13) 5 0.95 (0.39–2.29)
Endometrium 52 4.83 (3.68–6.34)
Ovary 31 0.71 (0.50–1.01)
Other female genital 6 2.04 (0.91–4.54)
Prostate 1454 1.41 (1.34–1.49)
Testis 2 0.98 (0.24–3.91)
Other male genital 11 0.81 (0.45–1.47)
Melanoma 23 2.61 (1.74–3.93) 107 1.18 (0.98–1.43)
Skin, squamous cell 53 1.64 (1.26–2.15) 272 1.30 (1.15–1.47)
Eye 5 1.98 (0.82–4.76) 13 3.62 (2.10–6.25)
Nervous system 24 1.24 (0.83–1.85) 70 26.3 (20.8–33.3)
Thyroid gland 6 0.72 (0.32–1.60) 19 1.69 (1.07–2.65)
Endocrine glands 27 1.87 (1.28–2.72) 34 1.72 (1.23–2.41)
Bone 3 0.40 (0.13–1.25)
Connective tissue 8 2.18 (1.09–4.37) 27 1.30 (0.89–1.90)
Hodgkin disease 2 2.54 (0.63–10.2) 9 6.92 (3.60–13.3)
Non-Hodgkin lymphoma 35 1.36 (0.98–1.90) 110 0.97 (0.80–1.17)
Myeloma 6 0.41 (0.18–0.92) 58 9.97 (7.70–12.9)
Leukaemia 36 4.53 (3.27–6.28) 121 1.16 (0.97–1.38)
Any non-smoking related 653 1.38 (1.28–1.49) 3005 2.85 (2.75–2.95)
Any site 1138 1.91 (1.80–2.03) 5060 2.77 (2.69–2.84)
Abbreviations: CI¼confidence interval; SIR¼standardised incidence ratio. Only tumours diagnosed at least one year apart were included in the calculations. Bold type
represents a significant increase at the 5% confidence level.
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sscreening trial (Rusthoven et al, 2008). These data indicate that
men affected by other tobacco-related cancers, in particular by
stomach, larynx and lung tumours, belong to the population at
high-risk for bladder cancer.
We found a borderline increased risk of bladder cancer
(SIR¼1.61) in women affected by non-Hodgkin lymphoma,
the SIR was 1.95 for male patients. These estimates were slightly
higher than the overall SIR of 1.50 found in an international study,
which included part of the Swedish cohort (Brennan et al, 2005;
Hemminki et al, 2008). International studies take benefit from a
large number of patients, but standard registration and homo-
geneity in treatment and exposure were important plus factors
of this study. The increase in risk with time since diagnosis in the
two studies underlines the effect of treatment for non-Hodgkin
lymphoma on the risk of second bladder neoplasms. Treatment
regimes for non-Hodgkin lymphoma typically involve chemo-
therapy with cyclophosphamide, which has been associated with a
4.5- to 10-fold increased risk of bladder cancer (Travis et al, 1995).
Localised radiotherapy may be also applied for low-grade subtypes
of lymphoma, which may additively interact with cyclophos-
phamide treatment. The present simultaneous consideration of age
at first diagnosis and time since diagnosis suggested that treatment
effects are particularly important when lymphomas are diagnosed
after 40 years of age. Cyclophosphamide is also used, often in
combination with other drugs, to treat leukaemia and this may
contribute to the increased SIRs we found among male leukaemia
patients (Simister, 1971).
Women affected by cervical cancer showed a large increase in
their risk of bladder tumours, and reversed analyses suggested an
important contribution of cervical cancer treatment. A recent
study that included Swedish data found an increased risk in
patients treated with and without radiotherapy (Chaturvedi et al,
2007). The SIRs around 4 have been reported in studies based on
women from the United States (Fisher et al, 1997). These data
were in agreement with these studies and indicated that survivors
of cervical cancer older than 65 years clearly belong to the
population at high-risk for bladder cancer. In general, cervical
cancer patients smoke more than women in the general popula-
tion, and some of the malignancies that were diagnosed close in
time were probably related to tobacco smoking. We observed that
the risk of bladder cancer increased among women affected
by tumours at other genital organs than the cervix, for example,
the endometrium.
Previous studies have shown that men with testicular cancer
continue to be at significantly an elevated risk of second bladder
cancer for more than two decades after initial diagnosis (Travis
et al, 1997). These data corroborated this result and showed that,
even 26–35 years after testicular cancer diagnosed before the age
of 40 years, the SIR was around 6. Although the estimated dose of
radiation to the bladder is generally higher after non-seminoma
than after seminoma treatment, studies that have taken the
histological type into account show similar SIRs after the two
types of germ-cell tumours. The use of radiotherapy fields to treat
testicular cancer has decreased in recent decades and lower doses
are used now. However, it has been hypothesised that cisplatin
may act as radiation enhancer and contribute to a shortened
latency periods for radiogenic bladder cancer. Histological
information is available in the Swedish Family-Cancer Database,
and future studies may add population-based evidence to this
respect.
The within-patient clustering of bladder and prostate tumours
has been extensively explored (Liauw et al, 2006; Bostrom and
Soloway, 2007; Kellen et al, 2007; Bostrom et al, 2008; Singh et al,
2008). In contrast with testicular cancer, which showed increasing
SIRs with increasing latency times, the SIRs of bladder neoplasms
decreased with the time after diagnosis of prostate cancer. The
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Figure 1 Age- and gender-specific incidence rates of urinary bladder cancer in the general population and in patients affected by selected types of cancer.
Only tumours diagnosed at least 1 year apart were included in the calculations. Results are presented for cancer sites with at least 100 patients affected by
bladder cancer as second malignancy and for age intervals with at least five observed cases.
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sTable 3 Number and SIRs of urinary bladder tumours in cancer patients according to age and age-of-diagnosis of first malignancy
Age of diagnosis of the first cancer
Any 20–39 years 40–59 years 60+ years
Cancer type (Gender) Age (years) N SIR (95% CI) N SIR (95% CI) N SIR (95% CI) N SIR (95% CI)
Recurrent neoplasms
Urinary bladder (females) 46–55 6 31.7 (14.2–70.8) 3 74.8 (24.1–232) 3 20.4 (6.56–63.3)
56–65 21 16.4 (10.7–25.2) 4 44.0 (16.5–118) 15 18.0 (10.8–29.9) 2 7.03 (1.76–28.1)
66–75 46 7.64 (5.71–10.2) 16 8.53 (5.22–13.9) 30 7.16 (5.00–10.3)
76–85 45 5.34 (3.97–7.16) 8 5.76 (2.88–11.5) 37 4.80 (3.47–6.64)
85+ 14 3.73 (2.20–6.32) 14 3.95 (2.33–6.70)
Urinary bladder (males) o45 7 68.6 (32.6–144) 4 40.9 (15.3–109) 2 99.4 (24.8– 399)
46–55 22 11.2 (7.37–17.0) 8 13.3 (6.66–26.7) 14 11.7 (6.92–19.8)
56–65 94 5.26 (4.29–6.44) 3 6.14 (1.98–19.0) 80 5.14 (4.12–6.40) 11 4.40 (2.43–7.95)
66–75 178 2.41 (2.08–2.80) 2 6.87 (1.72–27.5) 60 3.07 (2.38–3.96) 116 2.09 (1.74–2.51)
76–85 155 1.28 (1.09–1.50) 25 3.62 (2.44–5.36) 130 1.16 (0.98–1.38)
85+ 45 1.38 (1.03–1.86) 3 2.43 (0.78–7.55) 42 1.33 (0.98–1.81)
Renal pelvis (females and males) o45 1 189 (26.6–1344) 1 618 (86.6–4413)
46–55 11 114 (63.3–207) 1 11.6 (1.63–82.4) 10 343 (184–638)
56–65 27 35.1 (24.1–51.2) 1 15.6 (2.19–110) 13 23.7 (13.8–40.8) 13 164 (95.4–283)
66–75 56 23.3 (17.9–30.2) 5 5.65 (2.35–13.6) 51 32.7 (24.8–43.0)
76–85 54 15.6 (11.9–20.4) 3 10.1 (3.25–31.2) 51 17.6 (13.3–23.1)
85+ 7 8.97 (4.27–18.8) 7 9.34 (4.45–19.6)
Smoking-related cancer sites (excluding recurrent neoplasms)
Lung (females and males) 46–55 2 6.58 (1.65–26.3) 2 9.90 (2.47–39.6)
56–65 21 2.93 (1.91–4.50) 1 14.8 (2.08–105) 17 2.83 (1.76–4.55) 3 1.80 (0.58–5.57)
66–75 46 2.30 (1.72–3.07) 9 1.46 (0.76–2.81) 37 2.49 (1.81–3.44)
76–85 44 2.21 (1.65–2.98) 5 1.92 (0.80–4.62) 39 2.18 (1.59–2.99)
85+ 6 2.58 (1.16–5.74) 6 2.78 (1.25–6.20)
Cervix (females) o45 1 5.62 (0.79–40.0) 1 5.63 (0.79–40.1)
46–55 17 5.42 (3.36–8.76) 10 5.70 (3.05–10.6) 7 5.46 (2.59–11.5)
56–65 63 5.83 (4.54–7.49) 23 6.97 (4.62–10.5) 39 4.88 (3.56– 6.7) 1 2.73 (0.38–19.4)
66–75 89 5.40 (4.37–6.67) 19 6.07 (3.87–9.54) 61 6.09 (4.73–7.85) 9 2.59 (1.35–4.98)
76–85 75 5.64 (4.48–7.09) 10 6.53 (3.51–12.2) 47 6.72 (5.04–8.97) 18 6.54 (4.11–10.4)
85+ 13 4.00 (2.32–6.92) 1 138 (19.4–981) 6 5.33 (2.39–11.9) 6 3.52 (1.58–7.87)
Renal parenchyma (females and males) 46–55 1 0.63 (0.09–4.44) 1 0.87 (0.12–6.19)
56–65 16 1.65 (1.01–2.69) 13 1.75 (1.01–3.01) 3 2.40 (0.77–7.45)
66–75 45 1.72 (1.28–2.30) 19 1.99 (1.27–3.12) 26 1.65 (1.12–2.42)
76–85 42 1.42 (1.05–1.93) 1 12.8 (1.80–90.9) 6 1.13 (0.51–2.51) 35 1.46 (1.05–2.04)
85+ 5 0.94 (0.39–2.27) 1 1.56 (0.22–11.1) 4 0.88 (0.33–2.35)
Non-smoking-related cancer sites
Colorectum (females and males) o45 3 4.57 (1.47–14.2) 1 4.45 (0.63–31.6) 2 27.1 (6.75–108)
46–55 10 2.92 (1.57–5.44) 1 1.38 (0.19–9.80) 9 4.12 (2.14–7.93)
56–65 35 1.57 (1.12–2.18) 3 2.15 (0.69–6.68) 24 1.38 (0.92–2.06) 8 1.54 (0.77–3.07)
66–75 161 1.50 (1.28–1.75) 41 1.63 (1.20–2.21) 120 1.60 (1.34–1.92)
76–85 236 1.33 (1.17–1.52) 26 1.60 (1.09–2.35) 210 1.32 (1.15–1.51)
85+ 78 1.23 (0.98–1.54) 2 0.67 (0.17–2.67) 76 1.25 (1.00–1.57)
Breast (females) 46–55 16 2.10 (1.28–3.45) 2 1.29 (0.32–5.16) 14 2.07 (1.22–3.50)
56–65 72 1.71 (1.36–2.17) 3 1.01 (0.33–3.15) 59 1.63 (1.26–2.11) 10 2.44 (1.31–4.54)
66–75 101 1.25 (1.03–1.53) 2 1.10 (0.28–4.41) 38 0.89 (0.64–1.22) 61 1.42 (1.10–1.83)
76–85 122 1.38 (1.15–1.66) 30 1.75 (1.22–2.51) 92 1.34 (1.09–1.65)
85+ 41 1.33 (0.97–1.82) 3 0.76 (0.25–2.37) 38 1.37 (0.99–1.90)
Endometrium (females) o45 1 17.7 (2.49–126) 1 32.4 (4.54–231)
46–55 2 1.72 (0.43–6.87) 2 1.85 (0.46–7.42)
56–65 27 2.70 (1.84–3.94) 2 8.03 (2.01–32.1) 20 2.35 (1.51–3.65) 5 3.59 (1.49–8.65)
66–75 70 2.97 (2.34–3.76) 49 3.58 (2.70–4.75) 21 2.13 (1.39–3.27)
76–85 82 2.44 (1.96–3.04) 43 4.19 (3.10–5.66) 39 1.74 (1.27–2.39)
85+ 24 2.75 (1.83–4.13) 13 6.88 (3.98–11.9) 11 1.56 (0.86–2.84)
Prostate (males) 46–55 4 6.07 (2.28–16.2) 4 6.07 (2.28–16.2)
56–65 69 3.10 (2.44–3.93) 45 2.80 (2.09–3.75) 24 3.21 (2.15–4.79)
66–75 290 1.30 (1.16–1.46) 17 1.16 (0.72–1.86) 273 1.31 (1.16–1.48)
76–85 495 1.12 (1.02–1.22) 4 0.93 (0.35–2.49) 491 1.12 (1.02–1.23)
85+ 142 1.03 (0.87–1.22) 142 1.03 (0.87–1.22)
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sreversed analyses also suggested a major contribution of risk
factors shared by bladder and prostate tumours. Relevant to the
urological clinical practice, our results indicated that men older
than 60 years affected by prostate cancer show an excess of second
primary bladder tumours. Previous studies have shown that
detection bias may have an important role in the first year of
follow-up, and our results confirmed this statement (Kellen et al,
2007). Out of 1721 patients affected by bladder after prostate
cancer, (1721 1000)/1721¼42% were diagnosed with the two
tumours within 1 year. A similar proportion was observed when
the opposite sequence was investigated. Prostate cancer radio-
therapy has been suggested to induce secondary malignancies in
the bladder, but if radiation were a central issue, SIRs would
increase with follow-up time, and this trend was not observed
(Liauw et al, 2006).
Mutations in DNA repair genes (XRCC3) and variants in genes
coding for xenobiotic-transforming enzymes (NAT2, GSTM1,
GSTP1 and NQO1) have been shown to modify the susceptibility
to bladder cancer (Chao et al, 2006; Chaturvedi et al, 2007; Easton
et al, 2007; Figueroa et al, 2007; Kellen et al, 2007; Sanderson et al,
2007; Murta-Nascimento et al, 2007b). These variants may be
associated with an increased risk of cancer at additional sites. For
example, two meta-analyses that explored the relevance of GSTM1
null status on stomach cancer found a modest risk increase
(La Torre et al, 2005; Saadat, 2006). A recent genome-wide
association study identified a novel variant, which confers an
increased risk for both urinary bladder and lung cancers
(Kiemeney et al, 2008). These polymorphisms are relatively
common in Swedes, but the low penetrances conferred by the risk
alleles (genotype relative risks between 1.2 and 1.5) result in a
limited contribution of the variants to the increased risk of bladder
neoplasms among cancer patients.
These data may be used to design future studies that investigate
the effectiveness of bladder cancer screening in cancer patients.
Although the definition of the population at high risk depends on
multiple interacting factors, men older than 60 years of age and a
smoking history have been traditionally considered to be at high
risk (Grossman et al, 2005). The incidence of bladder cancer
among men of 60 years of age in the Swedish Family-Cancer
Database was around 60 cases per 10
5 person-years. The
combination of this figure with a smoking prevalence of 40%
(Stegmayr et al, 2005), and with an odds ratio of bladder cancer for
smokers versus non-smokers of five, results in an incidence of
bladder cancer of 115 cases per 10
5 person-years for men older
than 60 years with a smoking history. We drew a horizontal line on
Figure 1 to characterise the groups of high-risk patients according
to this criterion. As expected, bladder and renal pelvis cancer
patients show very high recurrence risks. After lung cancer, for
every 1000 survivors, approximately 5 developed secondary
bladder cancer in the age interval 80–85 years. The threshold of
100 cases per 10
5 person-years was reached at the age of 60–65
Table 3 (Continued)
Age of diagnosis of the first cancer
Any 20–39 years 40–59 years 60+ years
Cancer type (Gender) Age (years) N SIR (95% CI) N SIR (95% CI) N SIR (95% CI) N SIR (95% CI)
Testis (males) o45 3 2.81 (0.91–8.74) 3 3.15 (1.01–9.78)
46–55 10 2.43 (1.31–4.52) 8 3.12 (1.56–6.24) 2 1.66 (0.42–6.65)
56–65 21 2.93 (1.91–4.50) 13 6.20 (3.60–10.7) 7 1.84 (0.88–3.86) 1 13.1 (1.84–92.9)
66–75 22 2.41 (1.59–3.67) 13 6.33 (3.67–10.9) 9 1.96 (1.02–3.77)
76–85 8 2.68 (1.34–5.37) 6 3.72 (1.67–8.28) 2 3.23 (0.81–12.9)
85+ 1 2.99 (0.42–21.3) 1 4.07 (0.57–28.9)
Melanoma (females and males) o45 1 0.75 (0.10–5.30) 1 0.95 (0.13–6.73)
46–55 12 2.91 (1.65–5.13) 3 2.24 (0.72–6.96) 9 3.00 (1.56–5.77)
56–65 31 1.45 (1.02–2.06) 4 1.13 (0.43–3.02) 25 1.66 (1.12–2.45) 2 0.70 (0.18–2.80)
66–75 52 1.18 (0.90–1.54) 1 0.89 (0.12–6.30) 16 2.01 (1.23–3.28) 35 2.03 (1.46–2.83)
76–85 53 1.07 (0.82–1.40) 7 0.91 (0.43–1.91) 46 1.12 (0.84–1.50)
85+ 15 1.01 (0.61–1.68) 2 1.70 (0.43–6.81) 13 0.91 (0.53–1.57)
Skin, squamous cell (females and males) 56–65 13 1.33 (0.77–2.29) 1 0.40 (0.06–2.82) 10 1.32 (0.71–2.45) 2 1.17 (0.29–4.68)
66–75 58 1.44 (1.11–1.86) 13 1.15 (0.67–1.98) 45 1.62 (1.21–2.16)
76–85 131 1.60 (1.34–1.90) 9 1.84 (0.96–3.54) 122 1.59 (1.33–1.90)
85+ 70 1.56 (1.23–1.98) 1 1.01 (0.14–7.20) 69 1.56 (1.23–1.98)
Non-Hodgkin lymphoma (females and males) o45 4 6.43 (2.41–17.1) 3 7.07 (2.28–22.0)
46–55 5 1.97 (0.82–4.75) 3 4.83 (1.56–15.0) 2 0.96 (0.24–3.86)
56–65 24 1.95 (1.31–2.91) 4 4.36 (1.64–11.6) 19 1.89 (1.20–2.96) 1 0.96 (0.14–6.82)
66–75 49 1.87 (1.41–2.48) 1 10.8 (1.52–76.5) 19 3.02 (1.93–4.74) 29 1.42 (0.99–2.04)
76–85 33 1.07 (0.76–1.50) 3 7.07 (2.28–22.0) 6 2.61 (1.17–5.81) 27 0.92 (0.63–1.34)
85+ 14 2.20 (1.30–3.72) 2 4.24 (1.06–17.0) 12 2.00 (1.13–3.52)
Abbreviations: CI¼confidence interval; SIR¼standardised incidence ratio. Results are presented for categories with observed cases. Only tumours diagnosed at least one year
apart were included in the calculations. Bold type represents a significant increase at the 5% confidence level.
Table 4 Summary of major risk factors that may result in the
development of urinary bladder neoplasms in cancer patients
Risk factor Type of malignancy
Smoking Lung, larynx, oral cavity, oesophagus, anus, stomach, pancreas,
cervix and kidney cancers
Workplace Leukaemia, stomach and lung cancers (rubber workers)
exposures Cancer in the nasal cavity (textile workers)
Lung, renal pelvis and liver cancers (printing companies)
Chemotherapy Lymphomas, leukaemia, ovary and breast cancers
Radiation therapy Cervix, rectum, anus, testis and prostate cancers
Arsenic in water Lung and liver cancers
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Among women, high-risk groups consisted of cervical cancer
patients older than 55 years and endometrial cancer patients older
than 75 years. Note that absolute incidences among cancer patients
can be approximated by combining the SIRs in Table 3 with
population-specific incidence rates.
The present data may help urologists to assess the risk of
bladder neoplasms in cancer survivors, who are going to ask for
clinical advice with increasing frequency in the near future. Our
results should also guide future studies that investigate the
effectiveness
of bladder cancer screening in cancer patients. The contribution
of known genetic variants to the observed associations is
probably minor. Treatment of the first malignancy, in particular
chemotherapy with cyclophosphamide and cisplatin, and also
radiotherapy, probably have a larger impact. Smoking can be
instrumental in the development of bladder cancer after tumours
in tobacco-related sites.
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